Abstract
A method for measuring cellular concentrations of the anthracycline doxorubicin was developed. The assay involves cell lysis and protein degradation by detergent and proteinase K treatment followed by DNA hydrolysis using DNase I. Prior to high-performance liquid chromatography, samples are deproteinized by the addition of ZnSO4 and methanol. The assay is linear with respect to both the cellular drug content and the number of cells assayed over the ranges tested, and drug recovery is close to 100%. The method has a limit of detection of 50 fmol injected doxorubicin. Within run and between-day coefficients of variation have consistently been found to be in the 5% and 10% range, respectively, in different cell lines exposed to doxorubicin in vitro. The method has been evaluated in analyses of doxorubicin levels in mononuclear blood cells of patients. The assay offers several advantages over commonly used organic extraction techniques and may improve cellular drug monitoring during anthracycline therapy in patients.
Similar content being viewed by others
References
Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA (1989) Pharmacokinetics and pharmacodynamics of longterm continuous-infusion doxorubicin. Clin Pharmacol Ther 45: 340
Andersen A, Warren DJ, Slørdal L (1993) A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 15: 455
Baurain R, Zenebergh A, Trouet A (1978) Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. J Chromatogr 157: 331
Chambers SH, Bleehen NM, Watson JV (1984) Effect of cell density on intracellular adriamycin concentration and cytotoxicity in exponential and plateau phase EMT6 cells. Br J Cancer 49: 301
Chang BK, Brenner DE, Gutman R (1989) Dissociation of the verapamil-induced enhancement of doxorubicins cytotoxicity from changes in cellular accumulation or retention of doxorubicin in pancreatic cancer cell lines. Anticancer Res 9: 347
Cummings J, Smyth JF (1988) Pharmacology of adriamycin: the message to the clinician. Eur J Cancer Clin Oncol 24: 579
Cummings J, Merry S, Willmott N (1986) Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing Ridgway osteogenic sarcoma (ROS). Eur J Cancer Clin Oncol 22: 451
Cummings J, Willmott N, More I, Kerr DJ, Morrison JG, Kaye SB (1987) Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4′-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues. Biochem Pharmacol 36: 1521
Cummings J, Willmott N, Smyth JF (1991) The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 27: 532
DeGregorio MW, Holleran WM, Macher BA, Linker CA, Wilbur JR (1984) Kinetics and sensitivity of daunorubicin in patients with acute leukemia. Cancer Chemother Pharmacol 13: 230
Formelli F, Carsana R, Pollini C (1986) comparative pharmacokinetics and metabolism of doxorubicin and 4′-demethoxy-4′-O-methyldoxorubicin in tumor-bearing mice. Cancer Chemother Pharmacol 16: 15
Formelli F, Carsana R, Pollini C (1987) Pharmacokinetics of 4′-deoxy-4′-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. Cancer Res 47: 5401
Gewirtz DA, Yanovich S (1986) Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and daunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit. Biochem Pharmacol 35: 4059
Gewirtz DA, Yanovich S (1987) Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit. Biochem Pharmacol 36: 1793
Israel M, Sweatman TW, Seshadri R, Koseki Y (1989) Comparative uptake and retention of Adriamycin andN-Benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures. Cancer Chemother Pharmacol 25: 177
Kennedy KA, Siegfried JM, Sartorelli AC, Tritton TR (1983) Effects of anthracyclines on oxygenated and hypoxic tumor cells. Cancer Res 43: 54
Kokenberg E, Sonneveld P, Nooter K, Steuyt K van der, Lövenberg B (1986) Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis. Cancer Chemother Pharmacol 17: 63
Lee FYF, Sciandra J, Siemann DW (1989) A study of the mechanism of resistance to adriamycin in vivo. Glutathione metabolism, p-glycoprotein expression, and drug transport. Biochem Pharmacol 38:3697
Legha SS, Benjamin RS, Mackay B, et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133
Mahdadi R, Pommery N, Pommery J, Lhermitte M (1987) Quantitative determination of adriamycin in rat hepatocytes using a volatile extraction buffer, HPLC and fluorescence detection. Biomed Chromatogr 2: 91
Paul C, Baurain R, Gahrton G, Peterson C (1980) Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia. Cancer Lett 9: 263
Reed E, Ozols R, Tarone R, Yuspa SH, Poirier MC (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 84: 5024
Rose LM, Tillery KF, Dareer SME, Hill DL (1988) High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue. J Chromatogr 425: 419
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning. A laboratory manual (2nd edn) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
Schwartz HS (1973) A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem Med 7: 396
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C (1985) Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography. Cytometry 6: 143
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels JCM, Haanen C (1986) Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated haematopoietic cells. J Chromatogr 377: 415
Speth PAJ, Raijmakers RAP, Boezeman JBM, et al (1988) In vivio cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells. Eur J Cancer Clin Oncol 24: 667
Speth PAJ, Hoesel QGC van, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15: 15
Strauss JF, Kitchens RL, Patrizi VW, Frenkel EP (1980) Extraction and quantification of daunomycin and doxorubicin in tissues. J Chromatogr 221: 139
Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C (1990) Intracellular concentrations of anticancer drugs in leukemic cells in vitro versus in vivo. Cancer Chemother Pharmacol 25: 252
Takemura Y, Kobayashi H, Miyachi H, Hayashi K, Sekiguchi S, Ohnuma T (1991) The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro. Cancer Chemother Pharmacol 27: 417
Tidefelt U, Sundman-Engberg B, Paul C (1989) Comparison of the intracellular pharmacokinetics of doxorubicin and 4′-epi-doxorubicin in patients with acute leukemia. Cancer Chemother Pharmacol 24: 225
Zhang Y, Sweet KM, Sognier MA, Belli JA (1992) An enhanced ability for transforming adriamycin into a noncytotoxic form in a multidrug-resistant cell line (LZ-8). Biochem Pharmacol 44: 1869
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andersen, A., Warren, D.J. & Slørdal, L. Quantition of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration. Cancer Chemother. Pharmacol. 34, 197–202 (1994). https://doi.org/10.1007/BF00685077
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685077